<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"	
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/"
	>
<channel>
	<title>Nephrology &#187; The Doctor&#039;s Channel</title>
	<atom:link href="http://www.thedoctorschannel.com/channels/nephrology/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.thedoctorschannel.com</link>
	<description>Internet TV for Doctors</description>
	<lastBuildDate>Wed, 16 May 2012 23:34:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
			<item>
		<title>ACE inhibitors tied to increased angioedema risk</title>
		<link>http://www.thedoctorschannel.com/view/ace-inhibitors-tied-to-increased-angioedema-risk/</link>
		<pubDate>Tue, 15 May 2012 18:53:02 +0000</pubDate> 
				<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nephrology]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[ACE inhibitors]]></category>
		<category><![CDATA[angioedema]]></category>
		<category><![CDATA[angiotensin]]></category>
		<category><![CDATA[ARB]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=31793</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; Pooled data suggest that use of renin–angiotensin system (RAS) inhibitors, particularly angiotensin converting enzyme (ACE) inhibitors may increase the risk of angioedema, researchers report in an April 20th on-line paper in the American Journal of Cardiology. Nevertheless, Dr. Franz H. Messerli told Reuters Health by email, &#8220;ACE inhibitors are among -]]></description>
		
			<media:content duration="1:29" medium="video">
		<media:title><![CDATA[ACE inhibitors tied to increased angioedema risk]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; Pooled data suggest that use of renin–angiotensin system (RAS) inhibitors, particularly angiotensin converting enzyme (ACE) inhibitors may increase the risk of angioedema, researchers report in an April 20th on-line paper in the American Journal of Cardiology. Nevertheless, Dr. Franz H. Messerli told Reuters Health by email, &#8220;ACE inhibitors are among -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/ace-inhibitors-tied-to-increased-angioedema-risk/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/Thumbnail_20120515clinc003.jpg"/>
	<media:keywords><![CDATA[ACE inhibitors,angioedema,angiotensin,ARB]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Mixed results on fish oil for keeping hemodialysis grafts clear</title>
		<link>http://www.thedoctorschannel.com/view/mixed-results-on-fish-oil-for-keeping-hemodialysis-grafts-clear-4/</link>
		<pubDate>Thu, 03 May 2012 20:04:06 +0000</pubDate> 
				<category><![CDATA[Nephrology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[AV fistula]]></category>
		<category><![CDATA[Fish oil]]></category>
		<category><![CDATA[Graft]]></category>
		<category><![CDATA[hemodialysis]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=30847</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; In a large randomized study of hemodialysis patients with new arteriovenous grafts, daily fish oil supplementation didn&#8217;t improve long-term graft patency. However, those who took fish oil daily for 12 months did go a longer time without forming a blood clot, had half the rate of thrombosis, were less apt -]]></description>
		
			<media:content duration="1:39" medium="video">
		<media:title><![CDATA[Mixed results on fish oil for keeping hemodialysis grafts clear]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; In a large randomized study of hemodialysis patients with new arteriovenous grafts, daily fish oil supplementation didn&#8217;t improve long-term graft patency. However, those who took fish oil daily for 12 months did go a longer time without forming a blood clot, had half the rate of thrombosis, were less apt -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/mixed-results-on-fish-oil-for-keeping-hemodialysis-grafts-clear-4/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/05/Thumbnail_20120501clin002.jpg"/>
	<media:keywords><![CDATA[AV fistula,Fish oil,Graft,hemodialysis]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Partial nephrectomy best for older adults with early-stage kidney cancer</title>
		<link>http://www.thedoctorschannel.com/view/partial-nephrectomy-best-for-older-adults-with-early-stage-kidney-cancer/</link>
		<pubDate>Thu, 19 Apr 2012 21:48:04 +0000</pubDate> 
				<category><![CDATA[Nephrology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[Urology]]></category>
		<category><![CDATA[kidney cancer]]></category>
		<category><![CDATA[nephrectomy]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=28376</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Older patients with small localized kidney tumors treated with partial nephrectomy live longer than those treated with radical nephrectomy, a new study suggests. “The take home message for clinicians is that, whenever feasible from a technical perspective, partial nephrectomy appears to be the best treatment option for patients with early-stage -]]></description>
		
			<media:content duration="1:41" medium="video">
		<media:title><![CDATA[Partial nephrectomy best for older adults with early-stage kidney cancer]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Older patients with small localized kidney tumors treated with partial nephrectomy live longer than those treated with radical nephrectomy, a new study suggests. “The take home message for clinicians is that, whenever feasible from a technical perspective, partial nephrectomy appears to be the best treatment option for patients with early-stage -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/partial-nephrectomy-best-for-older-adults-with-early-stage-kidney-cancer/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120419clin002.jpg"/>
	<media:keywords><![CDATA[kidney cancer,nephrectomy]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Fibrates linked to increased creatinine levels in elderly patients</title>
		<link>http://www.thedoctorschannel.com/view/fibrates-linked-to-increased-creatinine-levels-in-elderly-patients/</link>
		<pubDate>Wed, 18 Apr 2012 21:04:00 +0000</pubDate> 
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nephrology]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[creatinine]]></category>
		<category><![CDATA[fibrates]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=28343</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – A population-based study conducted in Canada has uncovered an association between starting fibrate therapy and an increase in serum creatinine in older patients, along with a small increase in related hospitalizations. The findings are reported in the Annals of Internal Medicine for April 17 by Dr. Amit X. Garg, MD, -]]></description>
		
			<media:content duration="1:36" medium="video">
		<media:title><![CDATA[Fibrates linked to increased creatinine levels in elderly patients]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – A population-based study conducted in Canada has uncovered an association between starting fibrate therapy and an increase in serum creatinine in older patients, along with a small increase in related hospitalizations. The findings are reported in the Annals of Internal Medicine for April 17 by Dr. Amit X. Garg, MD, -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/fibrates-linked-to-increased-creatinine-levels-in-elderly-patients/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/Thumbnail_20120418epid001.jpg"/>
	<media:keywords><![CDATA[creatinine,fibrates]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Autologous stem cells prevent acute rejection in renal transplantation</title>
		<link>http://www.thedoctorschannel.com/view/autologous-stem-cells-prevent-acute-rejection-in-renal-transplantation/</link>
		<pubDate>Fri, 23 Mar 2012 14:52:28 +0000</pubDate> 
				<category><![CDATA[Nephrology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[kidney transplant]]></category>
		<category><![CDATA[stem cell]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27287</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Kidney transplant recipients who are inoculated with autologous marrow-derived mesenchymal stem cells (MSC) have less risk of organ rejection and of opportunistic infection than those given anti-IL-2 receptor antibody induction therapy, according to a report in the Journal of the American Medical Association for March 21. “Importantly, autologous MSC inoculum -]]></description>
		
			<media:content duration="1:36" medium="video">
		<media:title><![CDATA[Autologous stem cells prevent acute rejection in renal transplantation]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Kidney transplant recipients who are inoculated with autologous marrow-derived mesenchymal stem cells (MSC) have less risk of organ rejection and of opportunistic infection than those given anti-IL-2 receptor antibody induction therapy, according to a report in the Journal of the American Medical Association for March 21. “Importantly, autologous MSC inoculum -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/autologous-stem-cells-prevent-acute-rejection-in-renal-transplantation/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/03/Thumbnail_20120320drgd008.jpg"/>
	<media:keywords><![CDATA[kidney transplant,stem cell]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Avoid tight glycemic control in hyperglycemic preemies &#8212; for now</title>
		<link>http://www.thedoctorschannel.com/view/avoid-tight-glycemic-control-in-hyperglycemic-preemies-for-now/</link>
		<pubDate>Wed, 21 Mar 2012 20:58:02 +0000</pubDate> 
				<category><![CDATA[Nephrology]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Glycemic Control]]></category>
		<category><![CDATA[hyperglycemia]]></category>
		<category><![CDATA[preemies]]></category>
		<category><![CDATA[premature]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27182</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Tight glycemic control in preterm babies who develop hyperglycemia should be avoided for now, until more data on the risks and benefits are available, advise clinicians from New Zealand in a paper published online March 19 in Pediatrics. In a randomized study of hyperglycemic preterm infants, they found that tight -]]></description>
		
			<media:content duration="1:47" medium="video">
		<media:title><![CDATA[Avoid tight glycemic control in hyperglycemic preemies &#8212; for now]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Tight glycemic control in preterm babies who develop hyperglycemia should be avoided for now, until more data on the risks and benefits are available, advise clinicians from New Zealand in a paper published online March 19 in Pediatrics. In a randomized study of hyperglycemic preterm infants, they found that tight -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/avoid-tight-glycemic-control-in-hyperglycemic-preemies-for-now/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/03/Thumbnail_20120321clin002.jpg"/>
	<media:keywords><![CDATA[Glycemic Control,hyperglycemia,preemies,premature]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Advantages seen with cangrelor vs clopidogrel during PCI for ACS</title>
		<link>http://www.thedoctorschannel.com/view/advantages-seen-with-cangrelor-vs-clopidogrel-during-pci-for-acs/</link>
		<pubDate>Tue, 20 Mar 2012 16:51:26 +0000</pubDate> 
				<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nephrology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[acute coronary syndrome]]></category>
		<category><![CDATA[Cangrelor]]></category>
		<category><![CDATA[clopidogrel]]></category>
		<category><![CDATA[PCI]]></category>
		<category><![CDATA[platelet]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27040</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Early ischemic events are reduced in patients undergoing percutaneous coronary intervention for acute coronary syndrome when they’re treated with cangrelor rather than clopidogrel for platelet inhibition, researchers report in the February issue of the Americal Journal of Cardiology. “There was no increase in major bleeding, but there was an increase -]]></description>
		
			<media:content duration="1:32" medium="video">
		<media:title><![CDATA[Advantages seen with cangrelor vs clopidogrel during PCI for ACS]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Early ischemic events are reduced in patients undergoing percutaneous coronary intervention for acute coronary syndrome when they’re treated with cangrelor rather than clopidogrel for platelet inhibition, researchers report in the February issue of the Americal Journal of Cardiology. “There was no increase in major bleeding, but there was an increase -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/advantages-seen-with-cangrelor-vs-clopidogrel-during-pci-for-acs/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/03/Thumbnail_20120320drgd002.jpg"/>
	<media:keywords><![CDATA[ACS,acute coronary syndrome,Cangrelor,clopidogrel,PCI,platelet]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Antiplatelet therapy benefit doubtful in chronic kidney disease</title>
		<link>http://www.thedoctorschannel.com/view/antiplatelet-therapy-benefit-doubtful-in-chronic-kidney-disease/</link>
		<pubDate>Tue, 20 Mar 2012 16:51:12 +0000</pubDate> 
				<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nephrology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Antiplatelet therapy]]></category>
		<category><![CDATA[chronic kidney disease]]></category>
		<category><![CDATA[CKD]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27035</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Results of a meta-analysis indicate that patients with chronic kidney disease (CKD) derive little net benefit from antiplatelet therapy in terms of cardiovascular outcomes but may be put at increased risk for bleeding complications, according to a report in the March 20 issue of the Annals of Internal Medicine. “Bleeding -]]></description>
		
			<media:content duration="1:37" medium="video">
		<media:title><![CDATA[Antiplatelet therapy benefit doubtful in chronic kidney disease]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Results of a meta-analysis indicate that patients with chronic kidney disease (CKD) derive little net benefit from antiplatelet therapy in terms of cardiovascular outcomes but may be put at increased risk for bleeding complications, according to a report in the March 20 issue of the Annals of Internal Medicine. “Bleeding -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/antiplatelet-therapy-benefit-doubtful-in-chronic-kidney-disease/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/03/Thumbnail_20120319clin001.jpg"/>
	<media:keywords><![CDATA[Antiplatelet therapy,chronic kidney disease,CKD]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Size matters when it comes to success of RFA for renal tumors</title>
		<link>http://www.thedoctorschannel.com/view/size-matters-when-it-comes-to-success-of-rfa-for-renal-tumors/</link>
		<pubDate>Tue, 13 Mar 2012 21:44:35 +0000</pubDate> 
				<category><![CDATA[Nephrology]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[radiofrequency ablation]]></category>
		<category><![CDATA[renal tumors]]></category>
		<category><![CDATA[RFA]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=26569</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – The success of radiofrequency ablation (RFA) for small renal tumors is strongly dependent on tumor size, according to a study in the April issue of The Journal of Urology, available online now. Dr. Jeffrey Cadeddu who worked on the study told Reuters Health RFA is “very effective for the smaller -]]></description>
		
			<media:content duration="01:34" medium="video">
		<media:title><![CDATA[Size matters when it comes to success of RFA for renal tumors]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – The success of radiofrequency ablation (RFA) for small renal tumors is strongly dependent on tumor size, according to a study in the April issue of The Journal of Urology, available online now. Dr. Jeffrey Cadeddu who worked on the study told Reuters Health RFA is “very effective for the smaller -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/size-matters-when-it-comes-to-success-of-rfa-for-renal-tumors/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/03/Thumbnail_20120313drgd001.jpg"/>
	<media:keywords><![CDATA[radiofrequency ablation,renal tumors,RFA]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Renin-angiotensin blockade helpful in heart failure with renal disease</title>
		<link>http://www.thedoctorschannel.com/view/renin-angiotensin-blockade-helpful-in-heart-failure-with-renal-disease/</link>
		<pubDate>Fri, 09 Mar 2012 22:59:41 +0000</pubDate> 
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[Critical Care]]></category>
		<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[Hospitalist]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Nephrology]]></category>
		<category><![CDATA[Nurses/NP/PA]]></category>
		<category><![CDATA[Pharmacists]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[ACE inhibitor]]></category>
		<category><![CDATA[ARB]]></category>
		<category><![CDATA[chronic kidney disease]]></category>
		<category><![CDATA[CKD]]></category>
		<category><![CDATA[Heart Failure]]></category>
		<category><![CDATA[renin-angiotensin]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=26379</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – The benefit of renin-angiotensin system inhibition in systolic heart failure (HF) extends to older patients with chronic kidney disease (CKD), a new study suggests. The study found that being prescribed an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) at hospital discharge was associated with a “significant modest” 14% -]]></description>
		
			<media:content duration="1:43" medium="video">
		<media:title><![CDATA[Renin-angiotensin blockade helpful in heart failure with renal disease]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – The benefit of renin-angiotensin system inhibition in systolic heart failure (HF) extends to older patients with chronic kidney disease (CKD), a new study suggests. The study found that being prescribed an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) at hospital discharge was associated with a “significant modest” 14% -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/renin-angiotensin-blockade-helpful-in-heart-failure-with-renal-disease/" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/03/Thumbnail_20120309clin010.jpg"/>
	<media:keywords><![CDATA[ACE inhibitor,ARB,chronic kidney disease,CKD,Heart Failure,renin-angiotensin]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
	</channel>
</rss>
